Updated With International Perspective: Global Skin Cancer Burden Set to Surge Through 2050, Especially in Lower-SDI Regions

Skin cancers, including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), represent a growing and uneven global health burden, with both incidence rates and disability-adjusted life-years (DALYs) projected to rise substantially through 2050, according to a new study published as a letter in JAMA Dermatology.

The increase is expected to be especially pronounced in low- and middle-Socio-Demographic Index (SDI) regions.

For the study, researchers analyzed the Global Burden of Disease (GBD) 2023 estimates for malignant melanoma, SCC, and BCC. Outcomes included prevalence and DALYs. Subgroup analyses were conducted by sex, age group, and SDI (range, 0–1), defined as the geometric mean of indices of fertility in those younger than 25 years, education among those aged 15 years and older, and lag-distributed income per capita. They projected the estimates out to 2050.

In 2023, skin cancers showed geographical variation, with DALYs concentrated in high-SDI regions. Prevalence exhibited a similar trend: Melanoma was highest in Oceania, while SCC peaked in high-income Western countries, particularly the US. BCC was highest in Oceania, North America, and Northern Europe.

From 1990 to 2023, trends diverged across SDI levels, the study showed. Specifically, low- and middle-SDI regions demonstrated consistent increases in incidence across the three cancers, with pronounced melanoma growth (258.8% in East Asia and 274.6% in Andean Latin America). The high-income Asia-Pacific region showed similar upward trends. In contrast, the high-income North America region showed a divergent pattern: Melanoma incidence decreased (−10.5%), while SCC and BCC increased (154.1% and 34.6%, respectively).

Melanoma DALYs declined globally, particularly in high-SDI regions, the researchers report.

In contrast, SCC DALYs increased in low-SDI settings (93.2%). BCC DALYs remained stable but increased notably in East Asia (45.1%) and the high-income Asia-Pacific region (39.6%).

By sex, male prevalence rates were consistently higher across the three cancers. For melanoma, in 2023 there were 28.2 cases per 100,000 population in males and 25.6 cases per 100,000 population in females. Melanoma prevalence declined from 2010 to 2023 in both sexes. From 1990 to 2023, age-stratified analysis showed melanoma prevalence rising most steeply in older age groups (≥70 years), while younger cohorts (30–49 years) demonstrated declines.

What gives? Population growth was associated with the increasing case numbers for SCC and BCC, while epidemiological changes contributed more to melanoma prevalence increases, especially in low–middle and middle-SDI regions, according to decomposition analysis. Bayesian age-period-cohort projections indicate continued global burden increases through 2050, with melanoma DALYs rising from approximately 2 million in 2025 to more than 3.3 million in 2050, SCC DALYs increasing from 1.2 million in 2025 to 4.0 million in 2050, and BCC accounting for the highest total DALYs, approaching 5.0 million in 2050. Low- and middle-SDI regions are projected to experience steep growth trajectories across all three cancers, the study authors predict.

“These patterns align with the United States Cancer Statistics (1999–2021 melanoma age-adjusted incidence, 15.1–23.0 cases per 100,000 population) and the Australian Cancer Surveillance showing declining melanoma rates among individuals younger than 40 years alongside rising keratinocyte carcinoma burden,” the researchers conclude. “However, this GBD-based global analysis captures the rising burden in low- and middle-SDI regions—populations underrepresented in established high-income country registries.”

These differences may stem from differences in healthcare access and screening infrastructure across SDI levels, they note. “High-SDI regions benefit from well-established dermatological surveillance systems, routine skin examinations, and public awareness campaigns, facilitating earlier detection, whereas low- and middle-SDI settings often face limitations in specialized healthcare resources and population-based screening programs, potentially leading to underdiagnosis in early stages and contributing to the observed variations in incidence and prevalence patterns.”

Turning the Tide on the Growing and Uneven Global Skin Cancer Burden

US dermatologists agree that skin cancer continues to surge and offer some thoughts on how to turn the table.

Skin cancer is a preventable disease, stresses Jane Yoo, MD, MPP, FAAD, FACMS, a Dermatologist and Mohs Surgeon in New York City and a Spokesperson for The Skin Cancer Foundation. “These projections are a reminder that prevention only works where access exists, so the SDI disparity is not surprising,” Dr. Yoo says. “There needs to be equitable dermatologic infrastructure—screening, education, and access—in the regions where the burden is growing fastest.”

The declining melanoma rates in younger cohorts in high-income countries is encouraging, she adds. “This data reminds us that those gains are heavily infrastructure-dependent. Early detection works only when you have dermatologists, screening programs, and population awareness.”

The SCC trajectory is particularly alarming, Dr. Yoo notes. “It is a tripling of disease burden in 25 years, concentrated in populations least equipped to absorb it,” she says. “What this also underscores for me is the sunscreen access problem. If we’re serious about bending the curve in lower-SDI regions, the conversation has to include affordable, cosmetically acceptable, broad-spectrum photoprotection that works for diverse skin tones and climates.”

She adds, “When we’re looking at a projected surge in skin cancer burden in populations with darker skin tones and intense UV exposure, that regulatory lag has real consequences.”

“The projected rise in skin cancer over the next 25 years reflects the reality of an aging population with decades of cumulative UV exposure, as well as increasing use of immunosuppressive medications, Vishal Anil Patel, MD, FAAD, FACMS, the Director of Cutaneous Oncology at the GW Cancer Center, the Director of Dermatologic Surgery, GW Department of Dermatology, and an Associate Professor of Dermatology at George Washington University School of Medicine & Health Sciences in Washington, DC, tells TDD. “As dermatologic surgeons, we are seeing not only more early-stage skin cancers, but also increasingly complex and advanced disease presentations, underscoring the growing need for innovative therapies in the immunotherapy era.”

He adds, “Managing the expanding global burden of skin cancer will require earlier detection, improved access to care, and continued advances that reduce both mortality and surgical morbidity.”

Aaron S. Farberg, MD, FAAD, Chief Medical Officer and Founder at Bare Dermatol­ogy in Dallas, TX, and an Assistant Professor at the University of North Texas Health Science Center in Fort Worth, TX, also weighed in on the new report.

“As dermatologists, we must confront a stark reality: Skin cancer incidence and disability-adjusted life-years are projected to surge globally through 2050, particularly impacting low- and middle-sociodemographic index regions,” he tells TDD. “This escalating crisis underscores a severe global disparity, where high-SDI countries benefit from robust surveillance and early detection while underserved populations face critical resource limitations.”

Dr. Farberg notes, “With basal cell carcinoma approaching 5.0 million DALYs, squamous cell carcinoma hitting 4.0 million, and melanoma rising past 3.3 million by 2050, our current management frameworks face unprecedented strain.”

Expanding global screening is vital, he says, but we must also develop better treatments for skin cancer, though the deeply entrenched economics of lucrative procedures like Mohs surgery may hold us back from shifting our focus.

“Ultimately, to change the trajectory of this looming global burden, the medical community must actively push past the financial inertia and prioritize developing better, more advanced treatments for skin cancer,” he says.

International Perspective

“This new study examining the trends in cutaneous melanoma and keratinocyte carcinomas shows that incidence of skin cancer is rising across income levels worldwide with patients in middle- and low-income regions likely to face worse outcomes because of the limited resources in place to care for them,” says Dr. Maria Ivonne Arellano Mendoza, International League of Dermatological Societies (ILDS) Secretary-General and Head of Dermatology at Hospital General de Mexico. “The data also show that men and old adults (70+) experience higher increases in skin cancer prevalence with projections. This suggests that disability-adjusted life-years will continue to rise in low- and middle-income regions.”

The onus is on dermatology providers around the globe to improve access for these patients.

“The data should encourage us to help patients deal with limitations in their care by participating in and strengthening training programs for healthcare workers,” she tells TDD. “Education, screening, and diagnostic public campaigns are important initiatives because delays in diagnosis and treatment increase morbidity and mortality. International collaboration is key to this endeavor and in helping us ensure that disease registries and other surveillance systems have access to accurate global data.”

Skin cancer can often be prevented with the use of proper sun-protection measures, she says.

“It’s essential that the global dermatology community focuses on promoting the importance of sun protection, particularly for vulnerable communities, such as those working outdoors, patients with albinism, those with xeroderma pigmentosum or taking medication for long-term immunosuppression.”